Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

European Journal of Cancer

Volumn 36, Issue 1, 2000, Pages 61-67

  Nielsen, O S ^a   Judson, I ^b   Van Hoesel, Q ^c   Le Cesne, A ^d   Keizer, H J ^e   Blay, J Y ^f   Van Oosterom, A ^g   Radford, J A ^h   Svancarova L ⁱ   Krzemienlecki, K ^j   Hermans, C ^k   Van Glabbeke, M ^k   Oosterhuis, J W ^l   Verweij, J ^l  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CENTRE LÉON BÉRARD   (France)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ CANCER RESEARCH INSTITUTE   (Slovakia)

^j INSTITUTE OF ONCOLOGY   (Poland)

^k EORTC DATA CENTER   (Belgium)

^l ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Chemotherapy; High dose; Ifosfamide; Soft tissue sarcoma

Indexed keywords

BICARBONATE; IFOSFAMIDE; MESNA;

ACIDOSIS; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA;

EID: 18844475497     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00240-3     Document Type: Article

References (28)

1. Suit HD, van Groeningen CJ, Mankin HJ, Rosenberg AE. Sarcoma of the soft tissues. In Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford, Oxford University Press, 1995, 1917-1939.
2. Robinson M.H. The management of adult soft tissue sarcomas. Clin. Oncol. 6:1994;183-192.
3. Vraa S., Keller J., Nielsen O.S., Sneppen O., Jurik A.G., Jensen O.M. Prognostic factors in soft tissue sarcomas. the Aarhus experience Eur. J. Cancer. 34:1998;1876-1882.
4. Verweij J., Mouridsen H.T., Nielsen O.S.et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults. the EORTC point of view Crit. Rev. Oncol./Hematol. 20:1995;193-201.
5. O'Byrne K., Steward W.P. The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. Crit. Rev. Oncol./Hematol. 27:1998;221-227.
6. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults. meta-analysis of individual data Lancet. 350:1997;1647-1654.
7. Nielsen O.S., Dombernowsky P., Mouridsen H.et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br. J. Cancer. 78:1998;1634-1639.
8. Blackledge G., van Oosterom A.T., Mouridsen H.T.et al. Doxorubicin in relapsed soft tissue sarcoma. justification of phase II evaluation of new drugs in this disease: an EORTC Soft Tissue and Bone Sarcoma Group study Eur. J. Cancer. 26A:1990;139-141.
9. Bramwell V.H.C., Mouridsen H.T., Santoro A.et al. Cyclophosphamide versus ifosfamide. final report of a randomised phase II trial in adult soft tissue sarcomas Eur. J. Cancer. 23A:1987;311-323.
10. Le Cesne A., Antoine E., Spielmann M.et al. High-dose ifosfamide. circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas J. Clin. Oncol. 13:1995;1600-1608.
11. Rosen G., Forscher C., Lowenbraun S.et al. Synovial sarcoma. uniform response of metastases to high dose ifosfamide Cancer. 73:1994;2506-2511.
12. Benjamin R.S., Legha S.S., Patel S.R., Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone. the M.D. Anderson experience Cancer Chemother. Pharmacol. 31(Suppl. 2):1993;S174-S179.
13. Cerny T, Leyvraz S, Dazzi H, et al. Phase II trials of ifosfamide and mesna in advanced soft tissue sarcoma patients: a definite dose-response relationship. Proceedings 28th Annual Meeting of the American Society of Clinical Oncology, 1992.
14. Küpfer A., Aeschlimann C., Wermuth B., Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet. 343:1994;763-764.
15. Kaplan E., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
16. Vantongelen K., Rotmensz N., Van der Schueren E. Quality control of validity of data collected in clinical trials. Eur. J. Cancer Clin. Oncol. 8:1989;1241-1247.
17. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 2:1984;1281-1288.
18. Connelly E.F., Budd G.T. Ifosfamide in the treatment of soft tissue sarcomas. Seminars Oncol. 23:1996;16-21.
19. Patel S.R., Vadham-Raj S., Papadopolous N.et al. High-dose ifosfamide in body and soft tissue sarcomas. results of phase II and pilot studies - dose response and schedule dependence J. Clin. Oncol. 15:1997;2378-2384.
20. Antman K.H., Ryan L., Elias A., Sherman D., Grier H.E. Response to ifosfamide and mesna. 124 previously treated patients with metastatic or unresectable sarcoma J. Clin. Oncol. 7:1989;126-131.
21. Elias A.D., Eder J.P., Shea T., Begg C.B., Frei E. 3d., Antman K.H. High-dose ifosfamide with mesna uroprotection. a phase I study J. Clin. Oncol. 8:1990;170-178.
22. Reichardt P., Tilgner J., Hohenberger P., Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma. a phase II study J. Clin. Oncol. 16:1998;1438-1443.
23. Van Oosterom A.T., Krzemienlecki K., Nielsen O.S.et al. Randomized phase II study of the EORTC soft tissue and bone sarcoma group comparing two different ifosfamide regimens in chemotherapy untreated advanced soft tissue sarcoma patients. Proc. ASCO. 16:1997;496a.
24. Buesa J.M., Lopez-Pousa A., Martin J.et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult. a study of the Spanish Group for Research on Sarcomas (GEIS) Ann. Oncol. 9:1998;871-876.
25. Comandone A., Leone L., Oliva C.et al. Pharmacokinetics of ifosfamide administrated according to three different schedules in metastatic soft tissue and bone sarcomas. J. Chemother. 10:1998;385-393.
26. Palumbo R., Palmeri S., Antimi M., Raffo P., Villani G., Toma S. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann. Oncol. 8:1997;1159-1162.
27. De Pas T., De Braud F., Orlando L.et al. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas. is it feasible? Ann. Oncol. 9:1998;917-919.
28. Quezado Z.M., Wilson W.H., Cunnion R.E.et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann. Intern. Med. 118:1993;31-36.